Evidence map›Paper›PMID 39341979›Full record

Trial reportTherapeutic innovation & regulatory science2025

Experimental Study of the Promotional Implications of Proprietary Prescription Drug Names.

Susana Peinado, Amie C O'Donoghue, Kevin R Betts, Ryan S Paquin, Kristen Giombi, Jennifer E Arnold, Bridget J Kelly, Christine Davis

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Therapeutic innovation & regulatory science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Susana PeinadoRTI International, 3040 E. Cornwallis Road, PO Box 12194, Research Triangle Park, NC, 27709-2194, USA. speinado@rti.org.
Amie C O'DonoghueOffice of Prescription Drug Promotion, Office of Medical Policy, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, US.
Kevin R BettsOffice of Prescription Drug Promotion, Office of Medical Policy, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, US.
Ryan S PaquinRTI International, 3040 E. Cornwallis Road, PO Box 12194, Research Triangle Park, NC, 27709-2194, USA.
Kristen GiombiRTI International, 3040 E. Cornwallis Road, PO Box 12194, Research Triangle Park, NC, 27709-2194, USA.
Jennifer E ArnoldDepartment of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, USA.
Bridget J KellyRTI International, 3040 E. Cornwallis Road, PO Box 12194, Research Triangle Park, NC, 27709-2194, USA.
Christine DavisRTI International, 3040 E. Cornwallis Road, PO Box 12194, Research Triangle Park, NC, 27709-2194, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe meaning and characteristics embedded in proprietary drug names have the potential to affect name recall, perceptions of drug benefits and risks, and attitudes toward a drug. In this study, we examined: (1) whether names that reference the drug's medical indication affect consumers' and primary care physicians' (PCPs') perceptions of the drug and (2) whether names that overstate the drug's efficacy affect consumers' and PCPs' perceptions of the drug.

methodsWe conducted an online experiment with 455 PCPs and 450 consumers to test the effects of fictitious proprietary prescription drug names. Participants were randomized to view one neutral drug name, one name that overstated the drug's efficacy, and five names that referenced the drug's medical indication.

resultsNames that referenced the drug's medical indication and names that overstated the drug's benefit both influenced perceptions of efficacy and risk compared to neutral names. For several outcomes, names evoking medical indications had similar effects to those designed to overstate the drug's efficacy. The patterns of effects were similar for PCPs and consumers.

conclusionFindings suggest drug names alone can be sufficient to produce attitudes and risk and benefit perceptions about drugs, even in the absence of any information beyond the drug's medical indication.

Indexed as

Prescription DrugsAdultFemaleHumansMaleMiddle AgedPhysicians, Primary CareTerminology as TopicPrescription DrugsAttitudeBenefitDrug namesMedical indicationPerceptionRisk

Identifiers

PMID39341979

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.